The FDA has a new warning about GLP-1s and vision loss. Should you worry?

Live updates

1. 3h ago

   FDA adds rare vision-loss warning to Ozempic, Wegovy, Zepbound labels

   The FDA has ordered new warning labels on Ozempic, Wegovy and Zepbound about a rare eye condition that can cause permanent vision loss. The condition is non-arteritic anterior ischemic optic neuropathy, or NAION, which blocks blood flow to the optic nerve. Doctors do not yet know how GLP-1 drugs might contribute to the effect, and the agency says the warning is issued out of an abundance of caution. Patients should not stop medication without consulting a clinician.

   Why it matters

   GLP-1 medications are widely prescribed for diabetes and weight loss, so any vision-related safety signal affects millions of users. The label change follows reports of sudden vision loss associated with the drug class, though a causal link has not been established. Regulators are balancing a rare but serious risk against the established benefits of the medications.

   What is confirmed

   • The FDA ordered new warning labels on Ozempic and Wegovy over a rare risk of permanent vision loss.
   • The FDA ordered new eye risk warnings for Ozempic and Zepbound.
   • A rare eye condition that causes vision loss has been added to GLP-1 warning labels in the United States.
   • The FDA is making this warning out of an abundance of caution, and doctors still are not sure how these drugs could have this effect on the body.

   Still unconfirmed

   • GLP-1 drugs directly cause NAION or blindness.

   What to watch next

   • FDA publication of the final warning label text and any post-market study requirements.
   • Clinical studies determining whether GLP-1 use increases NAION incidence or whether the association is coincidental.
   • Updated prescribing guidance from diabetes and obesity specialty societies.
   Sources used for this update (10)

   1. www.dailymail.com — UK Home | Daily Mail Online
   2. www.yahoo.com — Yahoo
   3. www.ap.org — Best of the AP
   4. CNN — US FDA orders new eye risk warnings for Ozempic, Zepbound
   5. Fox Business — FDA orders new warning labels on Ozempic, Wegovy over rare risk of permanent vision loss
   6. The Washington Post — The FDA has a new warning about GLP-1s and vision loss. Should you worry?
   7. The Guardian — FDA warns of rare eye condition causing blindness from GLP-1 weight loss medications
   8. STAT — GLP-1s are given an FDA warning for rare eye condition risk
   9. www.aol.com — Do Ozempic, Zepbound cause vision loss? New FDA warning explained - AOL
   10. www.wesh.com — FDA’s new warning about GLP-1s and blindness explained
   confidence 92%